Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients

  • Shu, Jian (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Li, Cheng-Guang (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Liu, Yang-Chen (Department of Oncology, Tai Xing People's Hospital) ;
  • Yan, Xiao-Chun (Department of Medical Oncology, Huai An Cancer Hospital) ;
  • Xu, Xu (Department of Medical Oncology, Gaogang People's Hospital of Tai Zhou City) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Cao, Jie (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Li, Ying (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Lu, Yan-Yan (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Wu, Xue-Yan (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Liu, Jin (Department of Chemotherapy, Jiangsu Cancer Hospital) ;
  • Xiang, Jin (Department of Research, Jiangsu Cancer Hospital)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To compare expression level of serum tumor associated materials (TAM) with several conventional serum tumor biomarkers, eg., carcinoembryonic antigen (CEA), carbohydrate antigen19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein(AFP), in selected solid tumors. Methods: Patients diagnosed histologically or cytologically with liver, breast, esophageal, gastric, colorectal or pancreatic cancers were enrolled into this study. After diagnosis, the level of TAM was determined by chemical colorimetry, and levels of conventional tumor markers was measured by chemiluminescence methods. Results: A total of 560 patients were enrolled into this study. No statistically significant difference was detected in TAM and the above mentioned tumor biomarkers in terms of their positivity and negativity ( P>0. 05). Conclusions: Detection of TAM in liver, breast, esophageal, gastric, colorectal, and pancreatic cancer patients demonstrates a good accordance with CEA, CA199, CA153, and AFP, thus suggesting that further study is warranted to verify whether TAM could be a surrogate for these conventional biomarkers.

Keywords

References

  1. Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6. https://doi.org/10.1016/S0009-9120(03)00050-X
  2. Bosl GJ, Motzer RJ (1977). Testicular germ-cell cancer. N Engl J Med, 337, 242-51.
  3. Boucher D, Cournoyer D, Stanners CP, et al (1989). Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res, 49, 847-52.
  4. Duffy MJ (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47, 624-30.
  5. Duffy MJ (2006). Serum tumor markers in breast cancer: are they of clinical value? Clin Chem, 52, 345-51. https://doi.org/10.1373/clinchem.2005.059832
  6. Duffy MJ, Sturgeon C, Lamerz R, et al (2010). Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol, 21, 441-7. https://doi.org/10.1093/annonc/mdp332
  7. Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57-63. https://doi.org/10.1159/000048277
  8. Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76. https://doi.org/10.1002/anie.198812671
  9. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  10. Gold P, Freedman SO (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunologica ltolerance and absorption techniques. J Exp Med, 121, 439-62. https://doi.org/10.1084/jem.121.3.439
  11. Gold P, Freedman SO (1965). Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 122, 467-81. https://doi.org/10.1084/jem.122.3.467
  12. Goggins M (2005). Molecular markers of early pancreatic cancer. J Clin Oncol, 23, 4524-31. https://doi.org/10.1200/JCO.2005.19.711
  13. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pacific J Cancer Prev, (in press).
  14. Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47. https://doi.org/10.1023/A:1011086929064
  15. Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104. https://doi.org/10.1016/S1074-5521(97)90253-2
  16. Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60. https://doi.org/10.1038/nrc1251
  17. Huang XE, Li CG, Li Y, et al (2011). Weekly TP Regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pacific J Cancer Prev, 12, 2797-800.
  18. Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Med Frontiers of China, 5, 80-1.
  19. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
  20. Khien VV, Mao HV, Chinh TT, et al (2001). Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histologyproven hepatocellular carcinoma. Int J Biol Markers, 16, 105-11.
  21. Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34. https://doi.org/10.1074/jbc.M302741200
  22. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  23. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
  24. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum Tumor Associated Material (TAM) from non-small cell lung cancer patients. Asian Pacific J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  25. Liu ZM (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chin J Lab Med, 9, 129-33.
  26. Li Y, Yan PW, Huang XE, et al (2011). MDR1 Gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 12, 2405-9.
  27. MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60.
  28. Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24. https://doi.org/10.1021/bi00834a039
  29. Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71. https://doi.org/10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.0.CO;2-V
  30. Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70. https://doi.org/10.1093/glycob/cwg041
  31. Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60. https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<252::AID-CNCR2>3.0.CO;2-T
  32. Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19. https://doi.org/10.1016/0046-8177(90)90250-9
  33. Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway.com..
  34. Steinberg W (1990). The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol, 85, 350-5.
  35. Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33. https://doi.org/10.1016/0167-7799(94)90121-X
  36. Turner GA(1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71. https://doi.org/10.1016/0009-8981(92)90073-Y
  37. Wu W, Yao DF, Gu LH, et al (2006). Determination of hepatoma-specifc alpha-fetoprotein by a mini-column affnity chromatography method. Chin J Clin Lab Sci, 24, 10-2.
  38. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  39. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  40. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  41. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  42. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  43. Yao DF, Jiang DR, Huang ZW, et al (2000). Abnormal expressiom of hepatoma specifc $\gamma$-glutamyl transferase and alteration of $\gamma$-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer, 88, 761-9. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<761::AID-CNCR5>3.0.CO;2-5
  44. Yu DS, Huang XE, Zhou JN, et al (2012). A comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, (in press).
  45. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  46. Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I.Focus on gangliosides. Int J Cancer, 73, 42-9. https://doi.org/10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
  47. Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer,73, 50-6. https://doi.org/10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0
  48. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II study on voriconazole in treating chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pacific J Cancer Prev, (in press).
  49. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer vol.13, pp.11, 2012, https://doi.org/10.7314/APJCP.2012.13.11.5587
  2. Comparative Study on Transcatheter Arterial Chemoembolization, Portal Vein Embolization and High Intensity Focused Ultrasound Sequential Therapy for Patients vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6257
  3. ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6523
  4. Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4757
  5. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer vol.121, pp.10, 2013, https://doi.org/10.1111/apm.12131
  6. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  7. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  8. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  9. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  10. Serum Levels of CA15-3, AFP, CA19-9 and CEA Tumor Markers in Cancer Care and Treatment of Patients with Impaired Renal Function on Hemodialysis vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1597
  11. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1703
  12. Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2005
  13. (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2009
  14. Phase II Study of Pemetrexed as Second or Third Line Combined Chemotherapy in Patients with Colorectal Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2019
  15. ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2591
  16. Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2611
  17. Chemotherapy and Late Course Three Dimensional Conformal Radiotherapy for Treatment of Patients with Stage III Non-small Cell Lung Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2663
  18. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  19. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  20. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  21. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  22. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  23. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  24. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  25. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  26. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer vol.30, pp.1, 2013, https://doi.org/10.1007/s12032-013-0477-z
  27. Macrophages Promote Coal Tar Pitch Extract-induced Tumorigenesis of BEAS-2B Cells and Tumor Metastasis in Nude Mice Mediated by AP-1 vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4871
  28. Further Study on Pemetrexed based chemotherapy in Treating Patients with Advanced Gastric Cancer (AGC) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6587
  29. Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients vol.35, pp.4, 2014, https://doi.org/10.1007/s13277-013-1458-8
  30. A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer vol.10, pp.1, 2015, https://doi.org/10.1186/s11671-015-1153-3
  31. Alpha-fetoprotein (AFP) Elevation Gastric Adenocarcinoma and Importance of AFP Change in Tumor Response Evaluation vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2003
  32. Metformin May Improve the Prognosis of Patients with Pancreatic Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3937
  33. Serum sRANKL and sRANKL/OPG ratio: Novel biomarkers in non-small cell lung cancer vol.11, pp.3, 2016, https://doi.org/10.3892/ol.2016.4166
  34. Effects of α-zearalenol on the metabolome of two breast cancer cell lines by 1H-NMR approach vol.14, pp.3, 2018, https://doi.org/10.1007/s11306-018-1330-3